{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:10:02Z","timestamp":1789560602050,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dsx.2026.103466","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:27:39Z","timestamp":1784993259000},"page":"103466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2281-970X","authenticated-orcid":false,"given":"Anh Tuan","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Linh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran My Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dsx.2026.103466_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding John","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.dsx.2026.103466_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.dsx.2026.103466_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.dsx.2026.103466_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"14","key":"10.1016\/j.dsx.2026.103466_bib5","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.dsx.2026.103466_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/dom.12872","article-title":"Upper and\/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: incidence and consequences","volume":"19","author":"Horowitz","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2026.103466_bib7","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes Pillars"},{"issue":"6","key":"10.1016\/j.dsx.2026.103466_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/obr.70077","article-title":"A systematic review identifying critical evidence gaps in reporting dietary change in randomized controlled trials prescribing liraglutide, semaglutide, or tirzepatide","volume":"27","author":"Jansson","year":"2026","journal-title":"Obes Rev"},{"issue":"4","key":"10.1016\/j.dsx.2026.103466_bib9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.clnu.2022.01.024","article-title":"ESPEN practical guideline: clinical nutrition and hydration in geriatrics","volume":"41","author":"Volkert","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.dsx.2026.103466_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.dsx.2026.103466_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.14255","article-title":"Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes","volume":"23","author":"Gibbons","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"9","key":"10.1016\/j.dsx.2026.103466_bib12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2026.103466_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.dsx.2026.103466_bib14","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.dsx.2026.103466_bib15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2026.103466_bib16","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2026.103466_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjd.2023.10.370","article-title":"The effect of tirzepatide during weight loss on food intake, appetite, food preference and food craving in people with obesity","volume":"47","author":"Martin","year":"2023","journal-title":"Can J Diabetes"},{"issue":"7","key":"10.1016\/j.dsx.2026.103466_bib18","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1111\/dom.16395","article-title":"The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: a secondary analysis of a randomized controlled trial","volume":"27","author":"Richardson","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"21","key":"10.1016\/j.dsx.2026.103466_bib19","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.3390\/nu17213318","article-title":"Exploring dietary intake in adults with type 2 diabetes using GLP-1 receptor agonists: a cross-sectional analysis","volume":"17","author":"Ponzo","year":"2025","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.dsx.2026.103466_bib20","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1111\/dom.70063","article-title":"Impact of tirzepatide treatment on participant-reported food craving and food preference: secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction","volume":"27","author":"Kennedy","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"12","key":"10.1016\/j.dsx.2026.103466_bib21","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402126000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402126000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:48:27Z","timestamp":1789559307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402126000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1871402126000937"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2026.103466","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2026.103466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103466"}}